T1	Participants 74 136	anthracycline-pretreated patients with advanced breast cancer:
T2	Participants 275 299	metastatic breast cancer
T3	Participants 477 520	anthracycline-pretreated patients with MBC.
T4	Participants 1847 1887	women with anthracycline-pretreated MBC.
